Furthermore, there is considerable evidence suggesting that obesity adversely affects the response to IBD treatment, especially with biologics, such as TNF-α antagonists, and immunomodulators, such as azathioprine and 6-mercaptopurine [60]. This evidence concerns the gene TNF and inflammatory bowel disease.